Skip to main content
Equibles
GNLX logo

GNLX · GENELUX Corp · Metrics

Track GNLX — free

Use GNLX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GNLX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.98 -0.09 (-4.35%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company has experienced recurring losses from operations since inception and incurred a net loss of $18.4 million and cash used in operations of $12.5 million during the six months ended June 30, 2026. These factors raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$93.66M
Shares
45.25M
Volume · Oct 22 947.45K Avg daily vol (3M) 314.8K

GNLX metrics

70 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.98
Market cap
$93.66M

Price action

20 metrics
Price change (1W)
-10.8%
Price change (30D)
-20.7%
Price change (3M)
-30.1%
Price change (6M)
-18.5%
Price change (YTD)
-52.5%
Price change (1Y)
-69.2%
Trailing year
Price change (5Y)
—
52-week high
$8.24
52-week low
$2.07
Change from 52-week high
-74.9%
Change from 52-week low
+0.0%
Annualized volatility
78.0%
Annualized volatility (3M)
65.3%
Beta
2.1
RSI (14D)
32.0
Price vs SMA 50
-18.8%
Price vs SMA 200
-24.0%
Avg volume (3M)
301,885
Relative volume
2.8
Average dollar volume
$782,349

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
45.25M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
5.8
reciprocal yield 17.2%
FCF yield
-30.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-38.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-415,175.0%
Trailing 12 months
Net margin
-401,812.5%
Gross profit (TTM)
—
Operating profit (TTM)
−$36.42M
Net income (TTM)
−$35.60M
Trailing 12 months
Diluted EPS (TTM)
$-0.86
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.89
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.87
Operating cash flow per diluted share (TTM)
$-0.62
Free cash flow per diluted share (TTM)
$-0.70
Capital expenditures per diluted share (TTM)
$0.08
R&D per diluted share (TTM)
$0.55
Stock compensation per diluted share (TTM)
$0.15
Book value per share
$0.30

Growth

11 metrics
Revenue growth YoY
-95.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+18.5%
Year over year · more shares
Revenue CAGR (3Y)
-91.0%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-220.9%
Return on assets
-135.8%
Debt / equity
—
Current ratio
2.4
EBITDA (TTM)
—
Free cash flow (TTM)
−$28.68M
Quick ratio
2.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$9.18M
Total assets
$26.20M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$25.28M
Capital expenditures (TTM)
$3.41M
R&D (TTM)
$22.68M
SG&A (TTM)
—
Stock compensation (TTM)
$5.84M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
72
13F filer change QoQ
0
Institutional ownership
21.7%
Conviction holders (share of 13F filers)
1.4%
Crowding (high-turnover and private-fund holders)
9.5%
Private-fund adviser ownership
9.2%
Active holders' share change QoQ
+6.0%
Holder tenure
7.9
Price vs estimated holder cost
-61.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
4.9%

Short interest

3 metrics
Short interest
9.6%
Latest settlement · 20.4 days to cover
Days to cover
20.4d
Short-squeeze score
66 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$159,421
Insider-sentiment score
27 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1231457 CUSIP 36870H103 13F (30d) 13 filings 13 filers Visit website Investor relations